Evan Fertig, MD
Neurology · Portland, ORNPI 1275515918
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,442 of the $2,256 with a category attached, or 63.9%. UCB SA accounts for 64.7% of it on its own, with 2 other manufacturers making up the rest.
Across 15 payments — averaging $150.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$1K
- Neuropace, Inc.$781
- Medtronic$15
Across 28 payments — averaging $3098.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$52K
- SK Life Science, Inc.$26K
- Neurelis, Inc.$8K
- UCB, Inc.$1K
What the payments were for
- Travel & lodging$1,44264%
- Food & beverage$81436%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 10 | $1,460 |
| Neuropace, Inc. | 4 | $781 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,256 in reported general payments places this provider in the 70th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 51 | $57,762 |
| VimpatLacosamide | 23 | $51,318 |
| Rufinamide | 17 | $44,659 |
| Keppra XrLevetiracetam | 11 | $42,572 |
| AptiomEslicarbazepine Acetate | 19 | $36,081 |
| BriviactBrivaracetam | 15 | $27,470 |
| Lamotrigine ErLamotrigine | 31 | $21,737 |
| Lacosamide | 203 | $14,519 |
| Tegretol XrCarbamazepine | 18 | $12,714 |
| Levetiracetam | 298 | $12,514 |
| Felbamate | 30 | $10,734 |
| Clobazam | 72 | $6,033 |
| Zonisamide | 117 | $5,496 |
| Carbamazepine ErCarbamazepine | 49 | $5,200 |
| Lamotrigine | 150 | $3,790 |
Paid to pharmacies, not to this prescriber.
Other neurology in Portland
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
- Nizar ChahinPortland$57K
- Jeffrey KayePortland$54K
- Michelle CameronPortland$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.